BXC vs SBC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BXC exhibits severe fundamental deterioration, characterized by a Piotroski F-Score of 4/9 (Stable) but offset by a catastrophic collapse in earnings power. The stock trades at a massive premium to its Graham Number ($5.94) and Intrinsic Value ($0.14), with a current P/E of 2917.50 reflecting near-zero profitability. While the balance sheet remains liquid with a Current Ratio of 4.66, the consistent failure to meet earnings estimates (0/4 beats) and a -175.8% YoY EPS growth indicate a business in a deep cyclical or structural decline.
SBC presents a paradoxical profile: it is fundamentally undervalued with a P/E of 8.98 and a price below its Graham Number ($5.22), yet it exhibits weak financial health with a Piotroski F-Score of 3/9. While profitability margins are impressive (Gross Margin 73.32%), the company is facing negative revenue growth (-10.90%) and significant insider selling by the CEO. The disconnect between the 'Buy' analyst consensus and the bearish technical/insider trends suggests a high-risk value play with deteriorating fundamentals.
Compare Another Pair
Related Comparisons
BXC vs SBC: Head-to-Head Comparison
This page compares BlueLinx Holdings Inc. (BXC) and SBC Medical Group Holdings Incorporated (SBC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.